74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
XBiotech Inc
Closed
2.92 -6.11
Overview
Share price change
24h
Min
2.92
Max
3.09
Income | -5.5M -11M |
|---|---|
EPS | -0.345 |
Employees | 92 |
EBITDA | -5.5M -9.9M |
Next Earnings | 8 May 2025 |
|---|
Market Cap | -17M 91M |
|---|---|
Previous open | 9.03 |
Previous close | 2.92 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
XBiotech Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
XBiotech Inc Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
